Exelixis Inc Sales Revenue, Goods, Gross (Deprecated 2018-01-31)
Exelixis Inc (EXEL) reported Sales Revenue, Goods, Gross (Deprecated 2018-01-31) of $172.65 million for the 3-month period ending 2018-06-29, per its 10-Q filed 2018-08-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueGoodsGross · last filed 2018-08-01
- Exelixis Inc sales revenue, goods, gross (deprecated 2018-01-31) for the quarter ending 2018-06-29 was $172.65M, a 72.20% increase year-over-year.
- Exelixis Inc sales revenue, goods, gross (deprecated 2018-01-31) for the quarter ending 2018-03-30 was $159.44M, a 104.51% increase year-over-year.
- Exelixis Inc sales revenue, goods, gross (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $100.26M.
- Exelixis Inc sales revenue, goods, gross (deprecated 2018-01-31) for the quarter ending 2017-03-31 was $77.96M.
| Period end | Sales Revenue, Goods, Gross (Deprecated 2018-01-31) 3 month | Sales Revenue, Goods, Gross (Deprecated 2018-01-31) 6 month |
|---|---|---|
| 2018-06-29 | $172.65M 10-Q · filed 2018-08-01 | $332.08M 10-Q · filed 2018-08-01 |
| 2018-03-30 | $159.44M 10-Q · filed 2018-05-02 | |
| 2017-06-30 | $100.26M 10-Q · filed 2018-08-01 | $178.22M 10-Q · filed 2018-08-01 |
| 2017-03-31 | $77.96M 10-Q · filed 2018-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |